Egypt's health ministry struck a string of agreements and research discussions in Berlin on 10 and 11 October, centred on a long-term framework with the African Union Development Agency (AUDA-NEPAD) to expand local production of medicines and vaccines across Africa. The announcements came as Health and Population Minister Khaled Abdel Ghaffar held a series of meetings on the sidelines of the World Health Summit, held at Berlin's Hotel InterContinental from 11 to 13 October under the theme "From Crisis to Resilience: Innovating for Health," according to the summit's own programme, Daily News Egypt and the Egyptian Gazette.
This year's summit is one of the largest global health gatherings on the calendar, drawing more than 4,000 participants in person and a further 45,000 online, with over 400 speakers across more than 75 sessions and 65 side events, according to the World Health Summit's own site. Egypt used the gathering to advance three separate strands of cooperation: pharmaceutical manufacturing, epidemic surveillance, and health-economics research.
An Africa-wide framework for making medicines and vaccines locally
Abdel Ghaffar met Nardos Bekele-Thomas, chief executive of AUDA-NEPAD, the African Union's development agency, on 10 October to agree a long-term cooperation framework on the local production of medicines, vaccines and medical technologies across the continent, Daily News Egypt reported. The framework is intended to cover pharmaceutical regulation, technology transfer, supply-chain resilience, investment mobilisation, professional training and the broader strengthening of healthcare systems.
Neither side disclosed a specific implementation timeline, funding commitment or list of named projects in the announcement, and the agreement was described as a framework for cooperation rather than a finished manufacturing deal.
Disease surveillance cooperation with Germany
Separately, Abdel Ghaffar visited the Robert Koch Institute, Germany's national public health institute, in Berlin on 10 October, where the two sides discussed health security, epidemic surveillance, public health intelligence, early-warning systems and digital surveillance tools, the Egyptian Gazette said. Talks also covered laboratory capabilities in molecular diagnostics and genomic sequencing of emerging pathogens, as well as crisis management, outbreak preparedness, joint simulation exercises and expert exchange programmes.
Abdel Ghaffar suggested that Egypt, given its geographical position, "could serve as a promising regional hub for hosting joint training activities and events benefiting countries across Africa and the Middle East," according to the Egyptian Gazette's account of the meeting. The discussions did not result in a signed agreement, but were framed as building sustainable institutional partnerships between the two countries' health authorities.
Health-economics research with WifOR and Roche
On 11 October, Egypt's health ministry also discussed expanding research with the German WifOR Institute and the pharmaceutical company Roche under what ministry spokesperson Hossam Abdel Ghaffar described as the "Societal Value of Health" initiative, Daily News Egypt reported. The initiative has already produced two completed studies assessing treatments for breast cancer and for diabetic retinopathy, a diabetes-related eye condition that can lead to vision loss if untreated.
According to the ministry's own statement, as relayed by Daily News Egypt, the studies examined the "broader social and economic impact of treatments," including "patients' ability to remain in or return to work" and "improvements in productivity" — figures intended to show policymakers the wider value of specific treatments beyond their direct clinical cost. Officials discussed extending this type of research to other national health priorities and strengthening coordination between institutions for evidence-based health policymaking.
What it means for patients
None of the three strands of cooperation announced in Berlin will change what is available in Egyptian pharmacies or hospitals immediately — all were described as frameworks, discussions or completed research studies rather than finished projects with public rollout dates. But each points in a direction that matters for patients over time. A functioning Africa-wide framework on local medicine and vaccine manufacturing, if it progresses beyond this initial agreement, would feed into Egypt's long-running effort to secure more stable domestic supply of pharmaceuticals and reduce exposure to imported-medicine shortages and price swings.
Stronger surveillance cooperation with an institution such as the Robert Koch Institute would primarily affect how quickly Egypt's health system can detect and respond to emerging disease threats, rather than day-to-day care. The health-economics research with WifOR and Roche is the most directly policy-facing of the three: by quantifying the wider value of treatments for conditions such as breast cancer and diabetic retinopathy, it is intended to support evidence-based decisions on health policy, according to the ministry.
Frequently asked questions
What did Egypt agree with AUDA-NEPAD?
Egypt's health minister, Khaled Abdel Ghaffar, and AUDA-NEPAD chief executive Nardos Bekele-Thomas agreed a long-term framework on 10 October covering the local production of medicines, vaccines and medical technologies across Africa, including pharmaceutical regulation, technology transfer, supply-chain resilience, investment mobilisation and training. No specific projects, funding figures or timelines were disclosed.
What was discussed with Germany's Robert Koch Institute?
Abdel Ghaffar and the Robert Koch Institute discussed health security, epidemic surveillance, early-warning systems, laboratory capabilities such as molecular diagnostics and genomic sequencing, outbreak preparedness, joint simulation exercises and expert exchanges, with Egypt proposing itself as a potential regional hub for joint training.
What is the "Societal Value of Health" initiative?
It is a research effort with Germany's WifOR Institute and the pharmaceutical company Roche that measures the broader social and economic impact of medical treatments, including patients' ability to work and overall productivity. It has so far produced studies on breast cancer treatment and diabetic retinopathy treatment, with officials discussing extending it to other health priorities.
Does any of this affect patients in Egypt right now?
Not immediately. All three announcements from the Berlin summit were frameworks, discussions or completed research studies rather than finished programmes with public rollout dates, so there is no immediate change to medicine availability, hospital services or insurance coverage as a direct result of these specific announcements.
